– The second approval of a cancer drug for Exelixis – The approval of Exelixis/Roche drugs combination will save lives. – The melanoma the combination drugs treat is a killer with bad prognosis  – The terms of Exelixis/Roche agreement are favorable Reiterating our enthusiastic feeling about the future of Exelixis (EXEL), our feeling has transformed into reality and here we are, Swissmedic, the Swiss licensing …

As you would observe when reading the most recent Prohost Letters, our recent enthusiasm for Celldex Therapeutics (CLDX) emanated from its products’ combinationsc with novel immunotherapy drugs. In the past months, yesterday and today CLDX has outperformed for the same reason we mentioned in our most recent Prohost Letters. The reason for the current out-performance was the announcement that Celldex entered into a clinical trial …